Nyrada Inc. (ASX:NYR)
Australia · Delayed Price · Currency is AUD 0.2900
+0.0200 (7.41%)
Sep 5, 2025, 4:10 PM AEST
Nyrada Company Description
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases.
Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke.
Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.
Contact Details
Address: Sydney Place Sydney, Delaware 2000 Australia | |
| Phone | 61 2 9498 3390 |
| Website | nyrada.com |
Stock Details
| Ticker Symbol | NYR |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000070195 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James Bonnar | Chief Executive Officer |
| Cameron Peter Jones C.A. | Chief Financial Officer |
| Benjamin Evison Ph.D. | Chief Scientific Officer |
| Dimitri Burshtein | Investor Relations Manager |
| Mark Waring B.Sc., P.M.P. | Senior Vice President of US Operations |
| David James Franks BEc, C.A., F Fin, J.P. | Company Secretary |